No meetings
Consensus community valuation
XXXXXX
Average Intrinsic Value
XXXXXX
Overvalued by
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
Valuation of $4.97
Added 3 months ago

Quick and glancing look at results

EPS up 9.2% to 23.2c

At share price of $7.01 PE ratio is 30

Expected revenue growth of mid single digit after achieving 5% this year with similar margins

Doing a quick a DCF I get a valuation of $5 and that was being generous with growth and no margin safefy

Quick reverse DCF and need growth of 15-20% to justify current valuation.

This remains a trading stock (for me) because chart actually looks OK

Read More
#Business Model/Strategy
stale
Added 3 years ago

Dairy is important to the NZ economy. NZ is the biggest dairy exporter in the world making up 35% of the worlds dairy trade. NZ exports almost all production. 

What is dairy? It is more than milk, and unsurprisingly there are more than a few players. Since I spent time trying to understand this and A2, you get to read it too. 

Producers in NZ there some 11,000 farms across 1.7M hectares or around 6% of the landmass taking up a quarter of the pastural land to keep upwards of 5M cows fat and happy. These ladies produce 21B litres of milk annually which ultimately results in NZ$19B of export revenue which equates to about 20% of the national export revenue and getting close to half the agricultural export revenue.

China plays a huge part of this export consumption at around 40% although their consumptions is predominately powdered milk. High volume, low margin. It appears Ms Ardern hasn’t upset the Chinese like Morrison. The fact the Chinese government has told the population dairy is good for the immunity helped. 

While China is big, dairy exports go to more than 130 other countries with Australia, Indonesia key large markets. 

Processing – this is the world of Fonterra with 80% of the market and about 10 others making up the rest. Fonterra are focused on developing high margin products in medical, sport science and nutrition research such as fermented products.  

Distributors and Marketers – this is predominately the space a2 plays in although, like Fonterra they are across the whole supply chain. A place where quality, consistency and ESG are playing an increasingly importantly role. 

A2 Milk chair David Hearn recently said “While the issues that arose in FY21 were undoubtedly a challenge, the business remains at its heart a very robust, differentiated branded business with exceptionally strong financials.”

Understatement much?

The share price looks like a graph of flights through Auckland airport – ok possibly not that bad, but it is down 70% from ATH. That, and supply chain issues set off a chain of multiple profit downgrades.

Add in new leadership team and a Slater and Gordon class action distraction, shareholders went looking elsewhere. 

The strong Chinese market and a government attempt to stimulate the infant population again could help a2 although not immediately. The strong ESG and view that all things NZ are fresh and clean can contribute, although the Chinese government is pushing to increase local consumption. a2 remain embedded in the Chinese market and you need to put faith in this continuing.

While the company remains profitable, with net profit in FY20 NZ$385M on gross margins of 56%, falling to NZ$81M in FY21 on an also lower gross margin of 42%, it is not completely broken. Still, I would want to see the numbers climbing again and happily miss some upside to ensure there is not further downside. 


Read More
#Financials
stale
Last edited 3 years ago

I think today's news pretty much sums up A2's year. If I held I'd be jumping out as quickly as possible. As sentament is very much against A2 and feel the best way forward for holders now is a takeover and hope it comes to fruition for you all.

 

6/9/18

Adding on valuation grounds.

Continues to show strong growth in China and Australia plus ongoing expansion into the US attracts.

Nestle entry has shown no signs of impacting sales thus far

Read More
#Company Review
stale
Added 3 years ago

A2 share price rose by 12% today on speculation of a take over by Nestle.

I think no further action would take place with this until A2 releases there FY2021 report.

As mentioned in my valuation I am happy to hold and expect A2 to keep trading between $6-$8.
 

Risks
Theres no clear end of the lockdowns and travel restrictions preventing the return of the Diagou channel.
 

Market Cap                          5.5b NZ
Expected Revenue FY21    1.2b NZ
Expected EBTDA (11%)      132m NZ
ROE                                       27%
ROC                                      38%
 

I'll be interested to see information about direct sales into China in the upcoming FY2021 report.

Read More
#Bear Case
stale
Added 3 years ago

It is important to consider the headwinds generated from the increase in popularity of plant based "milks". In essence these often solve the problems that A2 is focused on. In my opinion the acceptance of these plant based alternatives and the plant based culture, especially with elite level athletes, is going to have a substantial impact on milk and all its byproducts. Just take note next time you are in the supermarket.

Read More
Valuation of $15.64
stale
Added 4 years ago
I found last weeks H1 FY21 results for A2M unsurprising and have hardly touched my FY21 expectations in updating my valuation. The Daigou impact is significant but considering international travel is all but stopped, sales have held up very well. Their recovery post Covid, the US market growth and continued strength in the ANZ market are the key issues short to medium term, but my valuation is base on the long term outlook covered below. First some points on the results: H1 FY21 Results Notes (NZ$): • Sales: $677m, down 16% on PCP, but down 27% on previous half due do de-stocking & Covid supply chain issues (read Daigou). Non-China labelled Infant Formula dropped 39% and now makes up 46% of sales, down from 64%. Mitigated by a third by a 45% increase in China labelled Infant Formula. USA based sales up 22% YOY, but still only 5% of sales! • Margins: 50.4%, down 6.8% to PCP, but half (3.4%) due to $23.3m inventory write down, so not good but not as bad as first print suggests, the balance due to higher Milk to Power sales ratio. • EBITDA: $175m down 30% on PCP. Includes 4.5m of acquisition costs for Mataura Valley Milk & 5.6m in FX loss, EBITDA% down 6.7% to a still healthy 26.4% the drop mitigated by good cost control. • Cashflow: Op Cashflow -9.2m Vs +160.6m YOY, driven by 147m increase in working capital in the half (AP drop of 90m most of it but Inv increase of 74m before write down is not good). Cash on hand of $775m is very healthy. • Outlook: FY21 1.4b Revenue & EBITDA Margins 24-26% (ex-acquisition costs aprox 10m). The outlook for FY21 assumes the actions being taken to re-activate the daigou/reseller channel delivers a significant improvement in quarter-on-quarter growth from 3Q21 to 4Q21. • Comment: Not bad considering! Full year I expected -15% Sales, EBITDA% of 25.4% and NPAT% of 17.5%. Margins are lower than I expected (due to inventory write offs) but operating costs have been moderated considerably to leave my full year expectations virtually unchanged (also my valuation). Business Outlook Factors • Great Business - High margin, capital light, high brand value, operating leverage, massive TAM opportunities in USA and China still, well run, shareholder aligned (minimum shareholding requirements for CEO and direct reports) – however David Hearn (Chair) sold about two thirds of his holding in Apr20, but still hold well over 1m shares. • Seeing some drift from pure marketing and brand business with addition of investments in producers – strategically makes sense but reduces business leverage, but not materially at this point. • US market growth and penetration is anaemic, real concerns that this will go the way of the UK and lead to A2M pulling out, but Covid is a massive issue in the US so 2020 was not a fair assessment. Profitability in the US improved from a loss of -30m to -11m, but H2 revenue is expected to be flat, so the US needs more time it seems. • China trade issues will hopefully be minor due to being a NZ company not Australian. The purchase of Mataura Valley Milks allows for additional China label registration to help further mitigate China regulatory (political) issues. However, note that Bellamy’s is now Chinese owned, so A2M may face unseen resistance in China when competing with Bellamy’s and China based infant power suppliers… • Science behind A2 – inconclusive, anecdotal at best and well short of proven benefits for users or those with lactose intolerance. None the less, the brand has built a strong image of being clean (NZ glow), healthy and worth the premium it charges for liquid and powdered milk – I expect this brand value to endure. • Competition in the A2 space is growing fast, but A2M has the name and lead which give it an advantage plus the additional competition actually helps grow what is still a new category so is not all bad. Valuation (DCF NZ$): • FY21 sales figures are a bit of a setback, I expect close to guidance of $1.47b but expect a strong recovery in FY22 to $1.86b, above FY20 as ANZ and China markets return to normal and grow. By 2030 I expect ANZ to get to 1.5b (+52% on FY20) on slow steady growth in a relatively mature market but dominant in category, China to $1.9b (+172% on FY20) strong growth in a large growing but competitive market and USA to $1.1 (up 1535% of a very low base, but less than ANZ or China) on strong growth but only a small player in a massive market. • Gross Margins I expect to remain strong but drift lower to 50% from mid 50’s due to competition and product mix changes (China label product with lower margins increasing) • Operating cost control I see as being maintained to support operating leverage with a healthy 26.4% EBITDA margin improving to 31.8% by 2030. • Capital spend I see as light, starting at 5m in FY21 and growing at 10%. This assumption may be wrong if there is further investment in producers, but if there is I would expect margin or sales growth upside from such investments to cover the additional capital costs. • Risk I weight at medium for a 10% discount rate and 20 EV/EBITDA value in 2030. Low risk factors are it has a lot of cash, is profitable and cash generating (current half an exception), sells a low risk stapple product that is always in demand. Offsetting high risk factors are geo-political and brand risk are higher than most businesses. Forecasted cashflows (NZ$m): 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 69 401 507 624 749 855 933 768 879 944 Terminal = 18,874 (EV/EBITDA = 20) Discount Rate = 10% IV = $16.82 (A$15.64 at 0.93 FX rate) I own A2M and made a mistake selling out at around $3 previously for a 50% gain rather than 10x, underestimating the business. I am probably scared by that experience so hesitant to sell, but I don’t expect it to be a 10 bagger, just a solid market beater long term.
Read More
#Quality on Sale?
stale
Added 4 years ago

Disclosure-I have a small holding, have been looking to add more.

The last result displays how much A2 relied on the retail daigou channel. this has been almost wiped out and IMO the big question going forward is will this channel re-establish itself and will it be as relevant.

BULL POINTS 

Smaller biz's like US and Aust Liquid milk doing ok. Brand still strong in China in IMF. Mgt trying to clean up inventory situation, took a $23m provision (enough?). Progress in MBS was good, although i consider this a good biz not a great biz. Corporate daigou seeing some green shots?

BEAR POINTS

Business momentum still negative, downgrading. Sales poor which is understandable given the situation but hard to accept mgt's initial bullish read. Hard to see high profitable growth without retail daigou, ie channel mix is deteriorating, mainly because retail daigou was so high. that is good but not great. the recent acquisition of MVM looks overly optimistic given the lower growth, hard to see it making sense in next several years. CBEC channel is problematic, pricing poor and inventory slooshing around. same for everyone. Competition has become tougher but with A2 at 2-3% share still room to grow.

WHERE TO FROM HERE

I think it is now obvious that the retail daigou channel made A2 a great biz and without it A2 is only a good biz. will this channel come back? probably needs intl borders reopened, which is not soon. will it still be as efficient and profitable?..dont know ..maybe. I think A2 is a good biz but I would like to buy it without paying for the retail daigou return. so that becomes the big potential upside. My best guess of this is good risk adjusted buying $7.50-8.

this is only an opinion not advice. DYOR

 

 

 

Read More
Valuation of $14.65
stale
Added 4 years ago
A2 is first and foremost a marketing company, and a very successful one at that. Per share revenues have climbed 3-fold in the past three years, with EPS up 4-fold. Capital light, with a strong brand, and massive net margins -- shares have climbed from $2 in 2016 to a high of $20 in 2020. However shares have taken a (big) hit with the covid-disrupted daigou channel expected to take a knife to first half sales, which are expected to drop by around ~7%. At the AGM today the company will reiterate FY guidance for FY sales growth of around 7% as conditions improve in the second half -- although the company acknowledges a lot of uncertanty. With vaccines on the way, and no structural issues, I think the current sell down has returned shares to more reasonable levels. Forecasting EPS of 65cps in FY23 (on the back of sustained margins and 10% sales growth after Fy21) and applying a PE of 30 to get a target price of $19.50. Discounting back by 10% pa to get a valuation of $14.65.
Read More
#Fundy/Analyst Views
stale
Added 5 years ago

22-May-2020:  https://www.livewiremarkets.com/wires/a2-milk-the-story-of-the-2-200-monster-next-door

Matt Joass from Maven Funds Management:  a2 Milk: The Story of the 2,200% Monster Next Door

"This is the story of how a little company from New Zealand grew to become a 14 billion dollar giant, the signs that indicated a big future ahead, and the tale of one of the greatest blunders in Australian business history. It is also the story of how we can apply the principles of what I call monster hunting to our own investing, and use the lessons on our quest to find the next potential winner while it is still small and undiscovered."

--- click on link above for the full livewiremarkets.com "wire" ---

Read More
Valuation of $15.45
stale
Added 5 years ago
Read More